Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981250 | 0.91 | PDE2A (0.40) | LCKPDE2ASRCFGFR1TLR7 | |
| SCHEMBL7983062 | 0.89 | LCK (0.50) | LCKPDE2AFGFR1TLR7 | |
| SCHEMBL7984047 | 0.89 | LCK (0.37) | LCKPDE2ASRCFGFR1TLR7 | |
| SCHEMBL7983002 | 0.86 | LCK (0.46) | LCKPDE2ASRCFGFR1TLR7 | |
| SCHEMBL7983240 | 0.85 | PDE2A (0.43) | LCKPDE2AFGFR1 | |
| SCHEMBL7979955 | 0.84 | LCK (0.54) | LCKPDE2AFGFR1 | |
| SCHEMBL7970474 | 0.84 | LCK (0.39) | LCKPDE2AFGFR1 | |
| SCHEMBL7969906 | 0.82 | LCK (0.37) | LCKPDE2A | |
| SCHEMBL7969597 | 0.81 | PDE2A (0.46) | LCKPDE2AFGFR1 | |
| SCHEMBL7981389 | 0.80 | FGFR1 (0.41) | LCKPDE2ASRCFGFR1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6235740-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATION AGENTS | BRISTOL-MYERS SQUIBB CO. | 2001-05-22 | — | — | US | claimed |
| US-6235740-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATION AGENTS | BRISTOL-MYERS SQUIBB CO. | 2001-05-22 | — | — | US | disclosed |